Reviews

Following the introduction of trade barriers by Western countries and the exit of some foreign drug manufacturers from the market, the Russian pharmaceutical market faced challenges, particularly in the innovative production of active pharmaceutical ingredients (API) for essential medications and insufficient funding for scientific research.